Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

20045,037 citationsJournal Articlebronze Open Access

Authors

David Cunningham · Royal Marsden NHS Foundation Trust

Yves Humblet · UCLouvain

Salvatore Siena · Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

David Khayat · Pitié-Salpêtrière Hospital

Harry Bleiberg · Institut Jules Bordet

Armando Santoro · Fondazione Humanitas per la Ricerca

D. Bets

Abstract

Cetuximab has clinically significant activity when given alone or in combination with irinotecan in patients with irinotecan-refractory colorectal cancer.

Topics & Keywords

Colorectal Cancer Treatments and Studies Lung Cancer Treatments and Mutations Gastric Cancer Management and Outcomes

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 351, Issue 4, pp. 337-345

DOI: 10.1056/nejmoa033025

Field-Weighted Citation Impact: 168.91